Lentigen Corporation, a biologics company, engages in the development and commercialization of lentiviral gene delivery products for human diseases for therapeutic, vaccine, and bioproduction applications. Acquired in 2014 by Miltenyi Biotec, a global provider of innovative solutions in biomedical research and cell and gene therapy, the firm operates as a wholly ownd subsiduary. Lentigen is a leading provider of custom lentiviral vectors for pre-clinical and clinical applications. The firm has set up working relationships with several high profile academic instiutions in the US and Europe and in July 2017 acquired another small firm in related space. The company's product pipeline includes treatment for chronic lymphocytic leukemia, glioblastoma, melanoma, and hemophilia A; vaccine preclinical programs and vaccine candidates, including virus like particles vaccines that target pandemic and seasonal influenza, Hepatitis C virus infection, and HIV/AIDS; and protein therapeutics that include the production of erythropoietin and factor VIII. It also has various programs on various stem cell types, such as hematopoietic (or blood making) stem cells (HSC) for the treatment of cancer and chronic infectious diseases; and programs to use mesenchymal stem cells (MSC) in the area of cancer therapy and regenerative medicine, as well Lentiviral vectors that express the genes to generate pluripotential stem (iPS) cell.
